Members
The GRK 2158 is composed of the Principal Inventors and PhD students from 14 teams from the fields of pharmacy, chemistry and medicine at Heinrich Heine University Düsseldorf (HHU).
Since 2016, the DFG has been funding 12 doctoral projects for 3 years each in 12 teams in pharmacy, chemistry and medicine. Associated scientists and Mercator Fellows as well as associated doctoral students contribute to the success of the scientific goals of the GRK.
Medical Faculty, Department of Pediatric Oncology, Hematology and Clinical Immunology
Project Cluster 2: Natural product/HDAC inhibitor-mediated modulation of immune responses and cytostatic-induced stress responses for resensitization of therapy-resistant tumors
Project Cluster 2: Natural product/HDAC inhibitor-mediated modulation of immune responses and cytostatic-induced stress responses for resensitization of therapy-resistant tumors
Institute of Pharmaceutical and Medicinal Chemistry
Project Cluster 4: Nisin as a model system to overcome lantibiotic resistance in bacterial pathogens.
Institute of Pharmaceutical Biology and Biotechnology
Project Cluster 3: Characterization of the mechanism of action and medicinal chemistry optimization of antimicrobial natural products (chloroflavonin, bisindole and indolo[3,2-a]phenazine)
Institute of Pharmaceutical and Medicinal Chemistry
Project Cluster 2: Natural product/HDAC inhibitor-mediated modulation of immune responses and cytostatic-induced stress responses for resensitization of therapy-resistant tumors
Institute of Pharmaceutical and Medicinal Chemistry
Project Cluster 2: Natural product/HDAC inhibitor-mediated modulation of immune responses and cytostatic-induced stress responses for resensitization of therapy-resistant tumors
Institute of Organic Chemistry and Macromoleculare Chemistry
Project Cluster 3: Characterization of the mechanism of action and medicinal chemistry optimization of antimicrobial natural products (chloroflavonin, bisindole and indolo[3,2-a]phenazine)
Institute of Medical Microbiology and Hospital Hygiene
Project Cluster 3: Characterization of the mechanism of action and medicinal chemistry optimization of antimicrobial natural products (chloroflavonin, bisindole and indolo[3,2-a]phenazine)
Institute of Bioorganic Chemistry
Project Cluster 1: Characterization and optimization of apoptosis- and autophagy-modulating natural products and derivatives for the elimination of therapy-resistant tumor cells
Institute of Medical Microbiology and Hospital Hygiene
Project Cluster 2: Natural product/HDAC inhibitor-mediated modulation of immune responses and cytostatic-induced stress responses for resensitization of therapy-resistant tumors
Project Cluster 4: Nisin as a model system to overcome lantibiotic resistance in bacterial pathogens.
Institute of Pharmaceutical and Medicinal Chemistry
Project Cluster 4: Nisin as a model system to overcome lantibiotic resistance in bacterial pathogens.
Institute of Molecular Medicine I
Project Cluster 1: Characterization and optimization of apoptosis- and autophagy-modulating natural products and derivatives for the elimination of therapy-resistant tumor cells
Institute of Molecular Medicine I
Project Cluster 1: Characterization and optimization of apoptosis- and autophagy-modulating natural products and derivatives for the elimination of therapy-resistant tumor cells
Project Title: Characterization of the molecular mechanisms underlying antibacterial activity of natural products
Project Area 3
Project Title: Modulation of the DNA damage response (DDR) by natural compounds (NC) to widen the therapeutic window of anticancer drugs
Project area 2
Project Title: Characterization of synergy and resistance traits of HSP90 and HDAC inhibitors in leukemic cell lines
Project area 2
Project Title: Structure based drug design against Nisin resistance systems
Project Area 4
Project Title: Development of selective histone deacetylase inhibitors (HDACi) and HDAC-based targeted protein degraders (TPD)
Project Area 2
Project Title: The nisin resistance operon from S. agalactiae: A modelsystem to inhibit lantibiotic resistance in human pathogens
Project Area 4
Project Title: Diversity-oriented synthesis of biheteroaryls as apoptosis inducers and biindole derivatives with variable (hetero)cyclic bridges against therapy resistant bacteria
Project Area 3
Project Title: Autophagy-modulating natural products – synthesis of tripyrrol-based derivatives
Project Area 1
Project Title: Multitargeting Approaches in Antimicrobial/Anticancer Drug Developments
Project Area 4
Project Title: Development of novel HDAC inhibitors to overcome resistance in therapy refractory childhood acute leukemia
Project Area 2
Project Title: Characterization of the molecular mechanisms underlying antibacterial activity of natural products
Project area 3
Project Title: Anticancer efficacy of combinations of histone deacetylase inhibitors and conventional and targeted anticancer therapeutics
Project area 2
Project Title: Identification and characterization of new agents with antimicrobial activity against apicomplexa and multidrug-resistant Gram-negative rod bacteria (4MRGN)
Project area 3
Project Title: Characterization of autophagy-modulating natural products and derivatives for the elimination of therapy-resistant tumor cells
Project area 1
Project Title: Elimination of anticancer drug resistant tumors by natural product drug induced cell death
Project area 1
Project Title: Elucidation of the mechanisms of action of immune‐activating HDAC inhibitors and natural products for the development of new therapeutic approaches against chemoresistant tumor cells and bacterial pathogens
Project area 2
Project Title: Nisin as a model system to overcome lantibiotic resistance in bacterial pathogens and molecular modeling to optimize antitumor and antimicrobial agents
Project Area 4
Project Title: Structure function relationship of the novel lantibiotic maddinglicin and its biosynthetic machinery
Project Title: Modulating protein-protein interactions to inhibit HDAC function selectively
Project Title: Inhibiting the CoREST complex with dual HDAC1,2 - LSD and protein-protein interaction inhibitors
Project Title: Biological Characterization of (class IIa) HDAC-Inhibitors with chemosensitising properties as anticancer agents
Project Title: Immunocompetent 3D pancreatic adenocarcinoma (PDAC) BioChip model for preclinical drug testing
Project Title: Synthesis of small-molecule inhibitors of nisin resistance protein
Project Title: Identification of novel apoptotic signaling pathways for the elimination of therapy-resistant tumors
Project Title: Targeting protein-protein interactions within the autophagy-inducing ULK1 complex for cancer therapy
Project Title: Targeting protein-protein interactions within the autophagy-inducing ULK1 complex for cancer therapy
Project Title: Modular synthesis of Indolophenazine-Derivatives as active agents against Toxoplasma gondii
Project Title: Preclinical development of IspC and IspH inhibitors of mevalonate-independent isoprenoid biosynthesis, including development of siderophore inhibitor conjugates and protein degraders.
Project Title: Characterization of the molecular mechanisms underlying antibacterial activity of natural products
Project Title: Development of subtype class I selective histone deacetylase inhibitors and degraders to revert and prevent therapy resistance in cancer.
Project description
Project Title: Diversity-oriented synthesis of novel Meriolins as apoptosis inducers for potential cancer treatment
Project Area 3
Project title: Characterization of autophagy-modulating HSP90 inhibitors
Project area 1 (Working Group of Björn Stork)
Project title: Klonierung des humanen CD40-L Gens für die Erzeugung eines rekombinanten
Mycobacterium bovis BCG Stamms für die therapeutische Tumorvakzinierung
Project area 3 (Working Group of Rainer Kalscheuer)
